You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)與諾華訂終止協議 重獲歐司珀利獨家權
百濟神州(06160.HK)公佈,與諾華簽署終止和釋放協議,公司將重新獲得在研TIGIT抑制劑歐司珀利單抗的開發、生產和商業化全部全球權利。 公司將繼續推進歐司珀利單抗與抗PD-1抗體替雷利珠單抗聯合用於治療PD-L1高表達且無致敏EGFR突變或ALK易位的一線局部晚期、不可切除或轉移性非小細胞肺癌(NSCLC)患者的3期AdvanTIG-302試驗的患者入組。由於治療方式發生變化,將停止一項比較歐司珀利單抗聯合替雷利珠單抗與度伐利尤單抗在治療同步放化療(cCRT)後III期不可切除NSCLC患者的3期AdvanTIG 301試驗。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account